4.4 Article

Long-Term Follow-up Investigation of Isolated Rapid Eye Movement Sleep Without Atonia Without Rapid Eye Movement Sleep Behavior Disorder: A Pilot Study

期刊

JOURNAL OF CLINICAL SLEEP MEDICINE
卷 11, 期 11, 页码 1273-+

出版社

AMER ACAD SLEEP MEDICINE
DOI: 10.5664/jcsm.5184

关键词

biomarker; EMG activity; polysomnography; REM sleep behavior disorder; SINBAR

资金

  1. Oesterreichische Nationalbank (Austria's central bank, Anniversary Fund) [15127]
  2. UCB [15127]
  3. Mundipharma, Respironics
  4. AbbVie
  5. Allergan
  6. Astra-Zeneca
  7. BIAL
  8. Boehringer-Ingelheim
  9. Boston Scientific
  10. GlaxoSmithKline
  11. Ipsen
  12. Lund-beck
  13. Medtronic
  14. MSD
  15. Merck-Serono
  16. Merz
  17. Novartis
  18. OrionPharma
  19. Teva

向作者/读者索取更多资源

Study Objectives: Idiopathic rapid eye movement (REM) sleep behavior disorder (RBD) is a harbinger of synuclein-mediated neurodegenerative diseases. It is unknown if this also applies to isolated REM sleep without atonia (RWA). We performed a long-term follow-up investigation of subjects with isolated RWA. Methods: Participants were recruited from 50 subjects with isolated RWA who were identified at the sleep laboratory of the Department of Neurology at the Medical University of Innsbruck between 2003 and 2005. Eligible subjects underwent follow-up clinical examination, polysomnography, and assessment of neurodegenerative biomarkers (cognitive impairment, finger speed deficit, impaired color vision, olfactory dysfunction, orthostatic hypotension, and substantia nigra hyperechogenicity). Results: After a mean of 8.6 +/- 0.9 y, 1 of 14 participating subjects (7.3%) progressed to RBD. Ten of 14 RWA subjects (71.4%) were positive for at least one neurodegenerative biomarker. Substantia nigra hyperechogenicity and presence of mild cognitive impairment were both present in 4 of 14 subjects with isolated RWA. Electromyographic activity measures increased significantly from baseline to follow-up polysomnography (any mentalis and both anterior tibialis muscles: 32.5 +/- 9.4 versus 52.2 +/- 16.6%; p = 0.004). Conclusion: This study provides first evidence that isolated RWA is an early biomarker of synuclein-mediated neurodegeneration. These results will have to be replicated in larger studies with longer observational periods. If confirmed, these disease findings have implications for defining at-risk cohorts for Parkinson disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据